Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2022, 31(3):196-201

Pulmonary embolism and Covid-19

Čambál D1, Molnárová K1, Petruą P1, Harąány J2, Klepanec A2
1 Oddelenie kardiológie, FN Trnava
2 Rádiologická klinika, FN Trnava, Slovenská republika

Aims: Patients with pulmonary embolism (PE) have different in-hospital mortality rates depending on their comorbidities and the grade of the obstruction of the pulmonary artery. In this study, we observed whether Covid-19 infection had a worsening impact on prognosis in patients affected by PE. We also analysed the significance of known risk factors such as Troponin levels, NTproBNP levels, D-dimer, arterial blood lactate, and CRP levels in patients with Covid-19 associated PE.

Methods: In this prospective cohort study, we observed patients hospitalised during the second wave of the Covid-19 pandemic in Trnava. Patients were divided into two groups, 1. patients with covid-19 associated PE (Covid+), and 2. patients with PE without Covid-19 infection as a control group (Covid-). We compared clinical findings, imaging findings, laboratory results and in-hospital mortality between these two groups.

Results: In this prospective study, we analysed data from 74 patients. Median age of patients was 69.5 (IQR 58-77). We identified 26 (35%) Covid+ patients. Covid+ patients had a longer hospitalisation [11 (IQR 8-17) days vs 8 (IQR 6.25-10) days, p = 0.004] and significantly higher in-hospital mortality than Covid-group (23% vs 2%, p=0.0065). The combined risk of in-hospital mortality and hemodynamic decompensation was similar in both groups (23% vs 8%, P=0.15). Nonfatal bleeding was reported overall in 4 patients (5.4%) without any significant difference between the two groups (8% vs 4%, p=0,6). From laboratory tests, only NT-proBNP levels had shown the difference between our groups. Despite lower levels of NT-proBNP in Covid + group [300.5 (182-2755.5) vs 1372 (5405420.5) pg/ml, p = 0.03], mortality rate was higher in these patients.

Conclusion: The Covid+ group had significantly higher in-hospital mortality, which pointed out the negative impact of Covid-19 infection on patients with PE.

Keywords: Covid-19; pulmonary embolism; in-hospital mortality

Published: March 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čambál D, Molnárová K, Petruą P, Harąány J, Klepanec A. Pulmonary embolism and Covid-19. Cardiology Letters. 2022;31(3):196-201.
Download citation

References

  1. Pellicori P, Doolub G, Wong CM, Lee KS, Mangion K, Ahmad M, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev 2021;3:CD013879. Go to original source...
  2. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041-1046. Go to original source...
  3. Jiménez D, Aujesky D, Moores L, Go´mez V, Lobo JL, Uresandi F, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010;170:1383-1389. Go to original source...
  4. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543-603. Go to original source...
  5. Lankeit M, Jimenez D, Kostrubiec M, et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014;43:1669-1677. Go to original source...
  6. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgicalpatients. J Thromb Haemost 2005;3:692-694. Go to original source...
  7. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107 I9-I16. Go to original source...
  8. Mestre-Gómez B, et al. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. J. Thromb. Thrombolysis 2020;51:40-46. Go to original source...
  9. Benito, N. et al. Pulmonary thrombosis or embolism in a large cohort of hospitalized patients with covid-19. Front. Med. 2020;7:557. Go to original source...
  10. Fauvel C, et al. Pulmonary embolism in COVID-19 patients: A French multicentre cohort study. Eur. Heart J. 2020;41:3058-3068. Go to original source...
  11. Bobadilla-Rosado LO, Mier Y, Teran-Ellis S, Lopez-Pena G, AnayaAyala JE, Hinojosa CA. Clinical Outcomes of Pulmonary Embolism in Mexican Patients With COVID-19. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211008988. doi: 10.1177/10760296211008988 Go to original source...
  12. Li P, Zhao W, Kaatz S, Latack K, Schultz L, Poisson L. Factors Associated With Risk of Postdischarge Thrombosis in Patients With COVID-19. JAMA Netw Open. 2021;4:e2135397 Go to original source...